Slide 1: A Leader in Critical Care Immunotherapy: Q4 and Full Year 2015 Earnings Call
Cyto Sorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q4 and Full Year 2015 Earnings Conference Call March 9, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward - looking statements and are subject to risks and uncertainties that could cause ac
Slide 3: CytoSorbents is A Leader in Critical Care Immunotherapy
3 Cyto Sorbents is A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life - Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb ® Blood Purification
Slide 4: CytoSorb Removes the Fuel to the Fire
4 Cyto Sorb ® Removes the Fuel to the Fire • CytoSorb ® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Clinically proven to remove key cytokines in the blood of critically -
Slide 5: Goal: To Prevent or Treat Organ Failure
5 Goal: To Prevent or Treat Organ Failure Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine Improve Patient Outcome and Survival Decrease Costs Of ICU and Patient Care
Slide 6: Operating and Financial Highlights
6 Operating and Financial Highlights
Slide 7: 2015 Comparative Revenue Results
7 2015 Comparative Revenue Results • CytoSorb ® product sales were $4.0M in 2015, a 29% increase over product sales of $3.1M in 2014 • Product sales were negatively impacted by the decline in the exchange rate of the Euro, which amounted to approximately $637K or 16% of product sales in 2015 • Grant
Slide 8: Quarterly Euro-Adjusted Product Sales
8 Quarterly “Euro - Adjusted” Product Sales $13,679 $87,960 $176,098 $127,969 $203,561 $314,159 $569,243 $663,233 $1,031,761 $871,150 $816,109 $920,041 1,221,694 $1,723,464 $0 $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 $1,400,000 $1,600,000 $1,800,000 $2,000,000 Q3 2012 Q4 2012 Q1 201
Slide 9: Working Capital and Cap Table
9 Working Capital and Cap Table 12/31/15 12/31/14 12/31/13 12/31/12 Current Assets: Cash and short-term investments 7,508$ 5,550$ 2,183$ 1,729$ Grants and accounts receivable, net 649 819 453 51 Inventories 1,191 538 245 682 Prepaid expenses and other current assets 512 700 605 476 Total current ass
Slide 10: Operating Highlights
Operating Highlights ~_ CytoSorhents
Slide 11: 3rd International CytoSorb Users Meeting
11 3 rd International CytoSorb Users Meeting • CytoSorbents will host its 3 rd International CytoSorb Users Meeting in Brussels, Belgium on March 14, 2016 • Currently, more than 100 people are registered to attend the meeting from a total of 22 countries • Agenda includes 12 clinical and pre - clini
Slide 12: 36th ISICEM Conference
12 36th ISICEM Conference • The International Symposium of Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium from March 15 - 18, 2016 is one of the largest, most prominent critical care conferences in the world • CytoSorbents is a Gold Sponsor and will exhibit and host a research s
Slide 13: Fresenius Medical Care and ISICEM
13 Fresenius Medical Care and ISICEM • Fresenius will initiate the marketing push behind CytoSorb ® at the ISICEM Conference in Brussels, Belgium next week ahead of a forthcoming launch • CytoSorb ® will be featured in the Fresenius exhibition booth on the multiFiltrate Acute Therapy System • Fresen
Slide 14: Biocon and Cardiac Surgery Partners
14 Biocon and Cardiac Surgery Partners • Biocon and CytoSorbents recently completed a four city, week - long trip in India and Sri Lanka with Prof. Dr. Zsolt Molnar, Chairman of SepsEast, the Central and Eastern European Sepsis Forum and experienced user of CytoSorb for critical illnesses • Introduc
Slide 15: REFRESH I Trial Update
15 • 40 - patient, eight - center study evaluating the safety and efficacy of intra - operative use of CytoSorb ® in a heart - lung machine during complex cardiac surgery in elective, non - emergent cardiac surgery > 3 hours • Aortic reconstruction, CABG redos, multiple valve replacements, etc • Goa
Slide 16: REFRESH I Trial Update: Sites and Enrollment
16 REFRESH I Trial Update RE duction in FRE e H emoglobin Trial • Working with major cardiac surgery centers • Baylor College of Medicine • Baystate Medical Center • Columbia University • Cooper University Hospital • University of Kentucky • University of Maryland • University of Pennsylvania • Univ
Slide 17: International CytoSorb Registry Update
17 International CytoSorb ® Registry Update • The CytoSorb registry is intended to collect treatment data from all over the world • It is funded by CytoSorbents, but is managed independently by the Center of Clinical Studies at University of Jena led by Prof. Dr. med. Frank Brunkhorst • The analysis
Slide 18: Sepsis Definition Update
18 Sepsis Definition Update The Third International Consensus Definitions Task Force just published their new guidelines for the definition of sepsis in JAMA* Sepsis was defined as: “The life - threatening organ dysfunction caused by a dysregulated host response to infection” • This aligns very well
Slide 19: Select Case Reports
Select Case Reports _ CytoSorhents
Slide 20: Refractory Septic Shock
20 Refractory Septic Shock At the 26 th Symposium for Intensive Medicine + Critical Care in Bremen, Germany, Dr. Sigrun Friesecke , Senior Intensivist in the Greifswald University Hospital MICU reported on a prospective, single arm study in 22 patients with refractory late - stage septic shock • Pat
Slide 21: Severe Burn Injury
21 Severe Burn Injury • 51 year old man was admitted and acutely treated for severe burn injury (60% BSA) and inhalation trauma due to an explosion accident • On Day 2, the patient developed acute kidney failure requiring dialysis • He subsequently developed shock requiring high doses of vasopressor
Slide 22: SIRS and Sepsis: Regain Control!
22 SIRS and Sepsis: Regain Control! Cyto Sorb ®
Slide 23: Contact and Q&A Session
23 Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 pchan@cytosorbents.com Cyto Sorbents Corporation NASDAQ: CTSO A Leader in Critical Care Immunotherapy Company Q&A Session